Quoin Pharmaceuticals

Historical price data

Quoin Pharmaceuticals is a clinical-stage company dedicated to addressing critical unmet needs in rare and orphan diseases, with a primary focus on severe skin barrier defects and vascular malformations. Its core achievement is the development of proprietary topical delivery systems for rapamycin, leading to its lead candidate, QRX003, which has secured multiple regulatory designations (Orphan Drug in US/EU, Rare Pediatric Disease) and is advancing in pivotal studies for Netherton Syndrome. The company's strategy combines targeted internal commercial infrastructure in key markets (US, Western Europe, Japan) with a network of nine exclusive marketing and distribution partnerships covering 61 additional countries to maximize global reach for its pipeline.

Proprietary topical formulation and delivery systems designed to achieve therapeutic loadings of rapamycin (sirolimus) and other compounds for localized treatment of skin barrier defects and vascular conditions.

Direct competition in Netherton Syndrome is minimal with no approved therapies. Broader competition includes off-label compounded topical rapamycin and other biopharma companies in rare dermatology, but Quoin's proprietary, clinically-validated formulations and regulatory exclusivity provide defensible advantages.